Hunan Hansen Pharmaceutical Co Ltd (002412) - Total Assets
Based on the latest financial reports, Hunan Hansen Pharmaceutical Co Ltd (002412) holds total assets worth CN¥2.73 Billion CNY (≈ $399.99 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Hunan Hansen Pharmaceutical Co Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Hunan Hansen Pharmaceutical Co Ltd - Total Assets Trend (2006–2025)
This chart illustrates how Hunan Hansen Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See what is Hunan Hansen Pharmaceutical Co Ltd's book value for net asset value and shareholders' equity analysis.
Hunan Hansen Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Hunan Hansen Pharmaceutical Co Ltd's total assets of CN¥2.73 Billion consist of 49.1% current assets and 50.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.3% |
| Accounts Receivable | CN¥282.22 Million | 10.5% |
| Inventory | CN¥208.44 Million | 7.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥28.66 Million | 1.1% |
| Goodwill | CN¥14.73 Million | 0.6% |
Asset Composition Trend (2006–2025)
This chart illustrates how Hunan Hansen Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Hunan Hansen Pharmaceutical Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Hansen Pharmaceutical Co Ltd's current assets represent 49.1% of total assets in 2025, a decrease from 58.7% in 2006.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2025, up from 2.8% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 6.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 10.5% of total assets.
Hunan Hansen Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Hunan Hansen Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Hunan Hansen Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.80 | 3.66 | 1.69 |
| Quick Ratio | 4.05 | 3.01 | 1.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.09 Billion | CN¥871.41 Million | CN¥243.33 Million |
Hunan Hansen Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hunan Hansen Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.32 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | CN¥2.69 Billion |
| Market Capitalization | $498.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Hansen Pharmaceutical Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hunan Hansen Pharmaceutical Co Ltd's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hunan Hansen Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total assets of Hunan Hansen Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.69 Billion ≈ $394.08 Million |
+5.73% |
| 2024-12-31 | CN¥2.55 Billion ≈ $372.74 Million |
+9.02% |
| 2023-12-31 | CN¥2.34 Billion ≈ $341.90 Million |
+1.99% |
| 2022-12-31 | CN¥2.29 Billion ≈ $335.24 Million |
+8.51% |
| 2021-12-31 | CN¥2.11 Billion ≈ $308.95 Million |
+11.79% |
| 2020-12-31 | CN¥1.89 Billion ≈ $276.37 Million |
+0.30% |
| 2019-12-31 | CN¥1.88 Billion ≈ $275.53 Million |
+4.70% |
| 2018-12-31 | CN¥1.80 Billion ≈ $263.16 Million |
+5.76% |
| 2017-12-31 | CN¥1.70 Billion ≈ $248.82 Million |
+1.55% |
| 2016-12-31 | CN¥1.67 Billion ≈ $245.02 Million |
+21.30% |
| 2015-12-31 | CN¥1.38 Billion ≈ $201.98 Million |
+0.92% |
| 2014-12-31 | CN¥1.37 Billion ≈ $200.15 Million |
+3.45% |
| 2013-12-31 | CN¥1.32 Billion ≈ $193.47 Million |
+26.90% |
| 2012-12-31 | CN¥1.04 Billion ≈ $152.46 Million |
+11.00% |
| 2011-12-31 | CN¥938.60 Million ≈ $137.35 Million |
-1.00% |
| 2010-12-31 | CN¥948.05 Million ≈ $138.73 Million |
+283.52% |
| 2009-12-31 | CN¥247.20 Million ≈ $36.17 Million |
+15.01% |
| 2008-12-31 | CN¥214.93 Million ≈ $31.45 Million |
+23.34% |
| 2007-12-31 | CN¥174.25 Million ≈ $25.50 Million |
-17.70% |
| 2006-12-31 | CN¥211.73 Million ≈ $30.98 Million |
-- |
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers digestive system medicines; cardiovascular and cerebrovascular medicines; kidney-tonifying and urine-reducing medicines; trauma medicines; diagnostic medicines, etc. It provides medicines in injection, mixture, tablet, capsule, granule, syru… Read more